QUICK ANSWER
Does Aetna Cover Foundayo?
Short answer: Coverage is forming. Foundayo (orforglipron) was FDA approved on April 1, 2026, making it one of the newest GLP-1 medications available. Most Aetna plans haven't added it to formularies yet, but self-funded employers have flexibility to add coverage independently.
What we know so far:
- Newer drug - CVS Caremark ended its new-to-market block on Foundayo on June 1, 2026 (CVS Caremark is Aetna's PBM); whether your plan covers it depends on your plan
- Self-funded employers have flexibility to add coverage independently
- Self-pay is affordable - $149–$299/month via LillyDirect (vs $1,000+ for injectable GLP-1s)
Why this is good news
Even without insurance coverage, Foundayo is one of the most affordable GLP-1 options available. With commercial insurance that covers Foundayo, the savings card can reduce your cost to as low as $25/month.
If You're Denied or Excluded
Many appeals succeed when properly documented. Whether you've been denied or are preparing for prior authorization, you have options.
Your GLP-1 coverage,
denied approved
✓ Free Templates✓ Premium Support Available
I was denied coverage for...
Get starteddenied approved
Honest Care helps patients fight back:
Evidence-backed appeal letters — plus personalized guidance to appeal with confidence.
WHY AETNA COVERAGE DEPENDS ON CVSThe CVS Caremark Connection
The CVS Caremark Connection
Understanding how Aetna makes drug coverage decisions helps explain your options.
CVS Health Owns Both Aetna and CVS Caremark
CVS Health acquired Aetna in 2018, and CVS Caremark manages pharmacy benefits for most Aetna plans. CVS Caremark's formulary decisions directly affect what Aetna plans cover.[1]
What This Means for Foundayo
Foundayo was FDA approved April 1, 2026. CVS Caremark ended its new-to-market block on Foundayo on June 1, 2026, so plans can now approve it for coverage. Whether your Aetna plan covers it depends on:
- Whether your plan has approved Foundayo for coverage
- Eli Lilly negotiates pricing and rebate terms
- Self-funded employers make independent decisions
CVS Caremark Has a Wegovy Preference Deal
CVS Caremark made Wegovy its preferred GLP-1 for weight loss on July 1, 2025, through a deal with Novo Nordisk.[2] Since October 1, 2026, Zepbound is back on CVS Caremark’s commercial template formularies as an additional preferred option (plan sponsors can customize), alongside Wegovy. Employers and plans can still customize their formulary, so check your own plan's formulary for Foundayo.
For more details: Complete CVS Caremark Guide
PLAN TYPE MATTERSHow Your Plan Type Affects Coverage
How Your Plan Type Affects Coverage
Your plan type often matters more than the default formulary. Here's what to expect based on GLP-1 coverage patterns:
| Plan Type | Coverage Status | Key Details |
|---|---|---|
| Self-Funded Employer | Varies | Employer controls formulary - ask HR |
| Standard Commercial | Varies | CVS Caremark ended its new-to-market block on June 1, 2026; check your plan's formulary |
| Advanced Control Plan | Varies | Follows CVS Caremark policies |
| ACA Marketplace | Usually excluded | Weight loss drugs typically excluded |
| Medicare Advantage | Bridge: $50 per monthly fill (with conditions) | Foundayo is covered by the Medicare GLP-1 Bridge (July 1, 2026 – December 31, 2027) for eligible MA-PD members |
| Medicaid | State-dependent | Each state sets own policies |
Status key: TBD/Varies = policy forming or employer-dependent Usually excluded = weight loss typically not covered
Self-Funded Employers - Your Best Chance
If you work for a large company (1,000+ employees), your employer may "self-fund" their health plan. This means your employer - not Aetna or CVS Caremark - decides whether drugs like Foundayo are covered.
Action: Ask your HR department: "Is our health plan self-funded or fully-insured?"
If self-funded, ask: "Can our plan add Foundayo coverage?"
Medicare - Through the Medicare GLP-1 Bridge
Medicare and weight-loss GLP-1s: the Medicare GLP-1 Bridge
Through the Medicare GLP-1 Bridge (July 1, 2026 – December 31, 2027), a temporary CMS demonstration that runs outside the Part D benefit, people with eligible Part D coverage can get Wegovy, Foundayo or the Zepbound KwikPen for weight loss for $50 a month, if they meet CMS’s eligibility criteria and their prescriber gets prior authorization.
Source: CMS, Medicare GLP-1 Bridge · Facts in this box verified October 5, 2026
FIND YOUR PATHBased on Your Situation
Based on Your Situation
Choose the path that matches your situation:
Still Checking Coverage?
Haven't verified your coverage yet or want to understand your options.
- Use our call script to verify with Aetna
- Ask HR if your plan is self-funded (more flexibility)
- Consider LillyDirect self-pay while coverage develops
Prior Auth Denied?
Your plan covers Foundayo, but your prior authorization was rejected.
- Many appeals succeed with proper documentation
- You have 180 days to file an appeal
- Request peer-to-peer review with Aetna medical director
Plan Excludes GLP-1s?
Your plan doesn't cover weight loss medications at all.
- Self-pay via LillyDirect - $149–$299/month
- Request formulary exception with medical documentation
- Ask HR about adding coverage (if self-funded)
Not Sure Which Applies?
If you've received a denial letter, check the language:
- "Not medically necessary" or "step therapy required" = PA denial (you can appeal)
- "Excluded benefit" or "not covered" = plan exclusion (different strategy needed)
WHAT TO EXPECT
Aetna Coverage Outlook for 2026
Coverage Is Forming
Foundayo was FDA approved April 1, 2026. Most insurers, including Aetna/CVS Caremark, are still developing coverage policies. This means:
- CVS Caremark ended its new-to-market block on Foundayo on June 1, 2026; check your plan's formulary
- Self-funded employers can add coverage anytime
- Self-pay via LillyDirect is available now
What to Watch For
CVS Caremark Formulary Updates
CVS Caremark updates formularies regularly. CVS Caremark ended its new-to-market block on Foundayo on June 1, 2026, where plans have approved it for coverage.
- Wegovy is preferred; Zepbound is a preferred option again since October 1, 2026
- Some plans may still exclude Foundayo
- Check with Aetna directly for current status
Self-Funded Employer Decisions
Self-funded employers can add Foundayo coverage independent of CVS Caremark decisions.
- Some employers are proactively adding GLP-1 coverage
- Benefits are often reviewed in Q3-Q4 for next year
- Ask HR about adding coverage during open enrollment
Medicare GLP-1 Bridge (live now)
CMS's Medicare GLP-1 Bridge (July 1, 2026 – December 31, 2027) covers Foundayo for $50 per monthly fill for Part D enrollees who meet CMS's eligibility criteria.
- Wegovy (injection and pill), Foundayo, and the Zepbound KwikPen
- Part D plans and pharmacies don’t opt in, and you don’t enroll separately; your prescriber must get prior authorization
- See Medicare coverage guide for updates
VERIFY YOUR COVERAGEHow to Check Your Aetna Coverage
How to Check Your Aetna Coverage
Call Aetna directly to confirm your specific plan's Foundayo coverage status.
Call Script for Aetna
"Hi, I'm calling to check coverage for a prescription medication. My member ID is [NUMBER]. I need to know:
- Is Foundayo (orforglipron) on my plan's formulary for weight management?
- If not yet added, when might formulary decisions be made for new drugs?
- Is my plan self-funded or fully-insured?
- What GLP-1 alternatives ARE covered on my plan?
- Can you send me the coverage policy in writing?"
Pro tip: Always request coverage criteria in writing. Verbal confirmations aren't binding.
Check Online
- Log in to your Aetna member account
- Go to "Find a Medication" or "Drug Lookup"
- Search for "Foundayo" or "orforglipron"
- Review your plan's coverage status
Self-Funded Employer? Talk to HR
If your employer self-funds their health plan, they decide what's covered. Here's how to advocate for coverage:
- Ask HR: "Is our plan self-funded? Can we add Foundayo coverage?"
- Make the case: Obesity treatment reduces long-term healthcare costs
- Time it right: Benefits are often reviewed in Q3-Q4 for the following year
IF COVEREDPrior Authorization Requirements
Prior Authorization Requirements
When Aetna covers GLP-1 medications for weight loss, prior authorization is typically required. Based on GLP-1 PA patterns, expect these requirements:
- BMI criteria: BMI 30+ (or BMI 27+ with hypertension, type 2 diabetes, sleep apnea, etc.)
- Lifestyle documentation: 3-6 months of documented diet and exercise efforts
- Step therapy (some plans): May require trying other medications first
- Renewal requirement: Typically must lose 5% body weight to continue coverage
Renewal Requirement - Plan Ahead
Most plans require you to lose at least 5% of starting body weight to continue coverage after the first authorization period. Document your progress throughout treatment.
PRIOR AUTH DENIED?How to Appeal a Denial
How to Appeal a Denial
If your plan covers Foundayo but your prior authorization was rejected, you can appeal.
Common Denial Reasons
- Medical necessity not met - How to document medical necessity
- Step therapy required - Step therapy guide
- BMI criteria not met - BMI documentation tips
- Missing lifestyle documentation - What you need
Aetna Appeal Basics
- Deadline: 180 days from denial to file internal appeal
- If internal fails: Request external review within 4 months (binding on Aetna)
- Tip: Request peer-to-peer review with Aetna's medical director
Complete Appeals Guide | External Review Process
Your GLP-1 coverage,
denied approved
✓ Free Templates✓ Premium Support Available
I was denied coverage for...
Get starteddenied approved
Honest Care helps patients fight back:
Evidence-backed appeal letters — plus personalized guidance to appeal with confidence.
AFFORDABLE OPTIONSIf Your Plan Excludes Foundayo
If Your Plan Excludes Foundayo
If Foundayo isn't covered by your Aetna plan, you have affordable alternatives:
Understanding the Savings Card
The Foundayo Savings Card works differently depending on your coverage:
| Your Situation | You Pay | Notes |
|---|---|---|
| With Commercial Coverage | $25/month | Insurance covers Foundayo + savings card |
| Without Coverage | $149–$299/month | Card reduces retail price to self-pay levels |
| Lapsed (45+ days) | $349/month | 14.5 mg and 17.2 mg doses if a refill is more than 45 days late |
| Medicare/Medicaid | Not eligible | Savings card excludes government plans |
Why Foundayo Self-Pay Makes Sense
At $149–$299/month, Foundayo is one of the most affordable GLP-1 options available:
- Injectable Wegovy: ~$1,350/month at retail
- Injectable Zepbound: ~$1,000/month at retail
- Foundayo: $149–$299/month via LillyDirect, by dose
AETNA FOUNDAYO COVERAGE
Frequently Asked Questions
Coverage is forming. Foundayo (orforglipron) was FDA approved April 1, 2026, making it one of the newest GLP-1 medications available. Most Aetna plans haven't added it to formularies yet. Self-funded employers have flexibility to add coverage independently. Check directly with Aetna for your plan's current status.
With Aetna coverage + savings card: As low as $25/month. Without coverage: $149–$299/month via LillyDirect, by dose. The savings card is valid through 12/31/2026 but is not available for Medicare or Medicaid enrollees.
Foundayo is brand new. It was FDA approved on April 1, 2026. CVS Caremark (Aetna's pharmacy benefit manager) evaluates new drugs for formulary inclusion based on clinical evidence, pricing negotiations with manufacturers, and comparison to existing options. CVS Caremark ended its new-to-market block on Foundayo on June 1, 2026, so whether your plan covers it now depends on your plan's formulary.
Yes, but pricing depends on coverage status. If Aetna covers Foundayo: as low as $25/month. If not covered: the savings card brings cost to $149–$299/month (not $25). The savings card is only available with commercial insurance and excludes Medicare/Medicaid enrollees.
Based on GLP-1 PA patterns, expect these requirements: BMI 30+ (or 27+ with hypertension, type 2 diabetes, sleep apnea, etc.), 3-6 months of documented lifestyle efforts, possible step therapy requirements, and a 5% weight loss renewal threshold. Requirements vary by plan - always get specific criteria in writing.
You have 180 days to file an internal appeal. Many appeals succeed with proper documentation including a Letter of Medical Necessity from your doctor, evidence of why alternatives won't work, and lifestyle documentation. If internal appeal fails, you can request an external review within 4 months - this is binding on Aetna. See our appeals guide for detailed strategies.
By law, basic Medicare Part D coverage excludes drugs used for weight loss, but Foundayo is covered by CMS’s Medicare GLP-1 Bridge (July 1, 2026 – December 31, 2027) for $50 per monthly fill, if you meet CMS’s eligibility criteria. Medicare enrollees who don’t qualify can pay cash through LillyDirect ($149–$299/month). See Medicare guide for details.
YOUR PATH FORWARD
What's Next
Foundayo Coverage: Other Major Insurers
See how other insurers compare:
- Blue Cross Blue Shield - 33+ independent companies, coverage varies
- UnitedHealthcare - Coverage policies forming
- Cigna - Check Express Scripts formulary
- Medicare - GLP-1 Bridge: $50 per monthly fill (with conditions)
Other GLP-1 Medications at Aetna
Aetna's coverage varies by medication. Compare your options:
References
- CVS Health. "About Aetna." https://www.cvshealth.com/about-cvs-health/aetna
- Managed Healthcare Executive. "CVS Caremark to Place Wegovy as Preferred GLP-1 for Weight Loss." May 2025. https://www.managedhealthcareexecutive.com
- Eli Lilly. "FDA approves Lilly's Foundayo (orforglipron)." April 1, 2026. Lilly Investor Relations
- Aetna. "GLP-1 Benefit Coverage." General employer-facing resource; does not contain specific PA criteria or formulary details. https://www.aetna.com/employers-organizations/glp1-benefits-coverage.html
- Centers for Medicare & Medicaid Services. Medicare Part D information. https://www.cms.gov/medicare/coverage/prescription-drug-coverage
Last updated October 6, 2026 · Key facts verified October 5, 2026
Disclaimer
The information on this page is for educational and informational purposes only and is not intended as medical advice. Honest Care does not provide medical diagnosis, treatment, or individualized recommendations. Always seek the advice of your physician or other qualified healthcare professional regarding any medical condition or treatment.
While this content has been reviewed for accuracy and balance, new evidence may emerge after publication. Drug availability, indications, and insurance coverage can change over time. Honest Care makes no warranties as to completeness or currentness of the information and is not responsible for decisions made based on this content.